Biogen Inc (BIIB)

$143.32 -1.54 (-1.06%)
Market Cap 21.24B
Revenue (ttm) 9.68B
Net Income (ttm) 1.63B
EPS (ttm) N/A
PE Ratio 9.30
Forward PE 9.38
Profit Margin 16.87%
Debt to Equity Ratio 0.36
Volume 1,425,251
Avg Vol 1,446,928
Day's Range N/A - N/A
Shares Out 146.62M
Stochastic %K 68%
Beta 0.11
Analysts Sell
Price Target $170.24

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar refer...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 617 679 2000
Address:
225 Binney Street, Cambridge, United States
dogDazeSummer
dogDazeSummer Sep. 14 at 4:18 PM
$IFRX $RHHBY $BIIB https://www.sciencedirect.com/science/article/abs/pii/S2387020625003985 Major need for more AAV solutions. Stadison knows the mechanism works as its FDA approved - low hanging fruit.
1 · Reply
GettnFibbywIT
GettnFibbywIT Sep. 12 at 6:06 AM
$BIIB $XLV $QQQ
0 · Reply
Chingying
Chingying Sep. 11 at 9:54 PM
$BIIB Biogen is finally getting the respect it deserves. If subcutaneous lequembi IQLIK is approved as an alternative for the 18-month treatment regime, it will greatly reduce the world’s burden to manage AZ disease.
0 · Reply
Quantumup
Quantumup Sep. 10 at 6:13 PM
Baird reiterated $SLNO Outperform/$121. Baird said: No change to outlook on FAERS update. The FAERS database was updated and now tragically has a listed death due to pulmonary embolism in a patient who was 17 years old, which management noted in an 8-K was considered by the physician to be not related to Vykat XR. Given comorbidities likely increasing baseline risk (lymphedema, superficial thrombophlebitis, obesity) and the physician's report as unrelated, we think the selloff here is far overdone and presents an even more attractive opportunity for investors to buy the launch on sale. $AARD $RYTM $ACAD $BIIB
0 · Reply
Quantumup
Quantumup Sep. 10 at 5:54 PM
TD Cowen reiterated $SLNO Buy/$120. TD Cowen said in its note: Three new SAEs for Vykat XR were uploaded to the FAERS database, which included a highly unfortunate death related to pulmonary embolism. The reporting physician does not consider this event as treatment-related, and $SLNO's assessment is the same. Pulmonary embolism risk is significantly increased in PWS and obese patients, and per our dinner with management last night, safety remains consistent. $AARD $RYTM $ACAD $BIIB
0 · Reply
iQuicky
iQuicky Sep. 9 at 9:30 PM
$BIIB coming back from death?
0 · Reply
StockAutoPro
StockAutoPro Sep. 9 at 7:50 PM
$BIIB: Buy target $141.05 Sell target $150.2 Strong drug pipeline suggests potential growth for this prominent biotechnology company.
0 · Reply
intrader
intrader Sep. 9 at 2:25 PM
$AVXL $BIIB $LLY $SNY
0 · Reply
Power2k
Power2k Sep. 9 at 2:09 PM
$AVXL No other Alzheimer's efficacy data (from any trials by $BIIB, $LLY, or $SNY ) ever came close to the data released by AVXL today. EMA approval is imminent.
1 · Reply
GettnFibbywIT
GettnFibbywIT Sep. 9 at 1:20 PM
$BIIB $XLV $QQQ Biogen, In.c / Daily: Rising, but still within (so far) the context of a longer term downtrend. A break /close above the upper channel/resistance line on continued underlying strength would initially suggest the trend "may" be changing....
0 · Reply
Latest News on BIIB
Biogen Inc. (BIIB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 6:51 PM EDT - 6 days ago

Biogen Inc. (BIIB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Global drugmakers rush to boost US presence as tariff threat looms

Sep 3, 2025, 2:09 PM EDT - 12 days ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN AZN GILD JNJ LLY MRK

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

Sep 2, 2025, 7:30 PM EDT - 12 days ago

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

Sep 2, 2025, 7:00 AM EDT - 13 days ago

Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

Sep 2, 2025, 7:00 AM EDT - 13 days ago

Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

STOK

These Stocks Are Moving the Most Today: Nvidia, Biogen, NIO, Spirit Aviation, and More

Sep 2, 2025, 4:54 AM EDT - 13 days ago

These Stocks Are Moving the Most Today: Nvidia, Biogen, NIO, Spirit Aviation, and More

NIO NVDA

US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug

Aug 29, 2025, 5:08 PM EDT - 17 days ago

US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Aug 29, 2025, 5:00 PM EDT - 17 days ago

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

FDA recommends more monitoring of Alzheimer's patients on Biogen's drug Leqembi

Aug 28, 2025, 2:16 PM EDT - 18 days ago

FDA recommends more monitoring of Alzheimer's patients on Biogen's drug Leqembi

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

Aug 25, 2025, 7:00 AM EDT - 21 days ago

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

STOK

Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

Aug 25, 2025, 7:00 AM EDT - 21 days ago

Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)

Aug 25, 2025, 3:00 AM EDT - 21 days ago

Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)

Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

Aug 11, 2025, 7:00 AM EDT - 5 weeks ago

Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

Aug 11, 2025, 7:00 AM EDT - 5 weeks ago

Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

STOK

Biogen: Strong Q2 Doesn't Change The Math On Eroding MS Portfolio

Aug 2, 2025, 9:15 AM EDT - 6 weeks ago

Biogen: Strong Q2 Doesn't Change The Math On Eroding MS Portfolio

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Aug 1, 2025, 8:31 AM EDT - 6 weeks ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

President Trump demands drugmakers slash prices within 60 days

Aug 1, 2025, 6:54 AM EDT - 6 weeks ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 2:24 PM EDT - 6 weeks ago

Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript

Biogen raises annual profit forecast on strong demand for rare disease drugs

Jul 31, 2025, 6:17 AM EDT - 6 weeks ago

Biogen raises annual profit forecast on strong demand for rare disease drugs

Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025

Jul 30, 2025, 11:00 AM EDT - 6 weeks ago

Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025

Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds

Jul 30, 2025, 8:12 AM EDT - 6 weeks ago

Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds

ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression

Jul 25, 2025, 7:20 AM EDT - 7 weeks ago

ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression

Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025

Jul 21, 2025, 7:30 PM EDT - 7 weeks ago

Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025

Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing

Jul 21, 2025, 2:25 PM EDT - 2 months ago

Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing

Biogen to invest $2 billion more in North Carolina

Jul 21, 2025, 7:41 AM EDT - 2 months ago

Biogen to invest $2 billion more in North Carolina

Biogen Announces $2 Billion Manufacturing Investment in North Carolina's Research Triangle Park in Conjunction with its 30th Anniversary

Jul 21, 2025, 7:30 AM EDT - 2 months ago

Biogen Announces $2 Billion Manufacturing Investment in North Carolina's Research Triangle Park in Conjunction with its 30th Anniversary

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

Jul 10, 2025, 7:00 AM EDT - 2 months ago

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

STOK

Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

Jul 10, 2025, 7:00 AM EDT - 2 months ago

Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

STOK

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

Jun 30, 2025, 7:30 AM EDT - 2 months ago

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA

Jun 27, 2025, 10:00 AM EDT - 2 months ago

New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

Jun 25, 2025, 7:30 AM EDT - 2 months ago

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

Biogen: Investors Are Missing The Bigger Picture

Jun 22, 2025, 10:27 PM EDT - 3 months ago

Biogen: Investors Are Missing The Bigger Picture

20 companies in the S&P 500 whose investors have gained the greatest rewards from stock buybacks

Jun 18, 2025, 11:13 AM EDT - 3 months ago

20 companies in the S&P 500 whose investors have gained the greatest rewards from stock buybacks

AAPL AIG AMAT AZO BK BKNG C

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

Jun 18, 2025, 7:30 AM EDT - 3 months ago

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity

Jun 12, 2025, 1:00 AM EDT - 3 months ago

Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity

Biogen Inc. (BIIB) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)

Jun 10, 2025, 1:50 PM EDT - 3 months ago

Biogen Inc. (BIIB) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

Jun 3, 2025, 7:00 AM EDT - 3 months ago

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

TRDA

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

May 28, 2025, 12:22 PM EDT - 3 months ago

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

AMGN DHR GILD IBB ILMN NVS SDGR

Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies

May 27, 2025, 7:30 AM EDT - 3 months ago

Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies

Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet

May 12, 2025, 12:30 PM EDT - 4 months ago

Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet

ABBV AMGN BMY GILD JNJ LLY MRK

Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal

May 12, 2025, 1:00 AM EDT - 4 months ago

Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal

MRK

Biogen Inc. (BIIB) Q1 2025 Earnings Call Transcript

May 1, 2025, 11:38 AM EDT - 4 months ago

Biogen Inc. (BIIB) Q1 2025 Earnings Call Transcript

Biogen beats quarterly profit estimates on strong demand for rare disease drugs

May 1, 2025, 6:48 AM EDT - 4 months ago

Biogen beats quarterly profit estimates on strong demand for rare disease drugs

Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent?

Apr 25, 2025, 9:15 AM EDT - 5 months ago

Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent?

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union

Apr 15, 2025, 7:00 PM EDT - 5 months ago

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union

EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease

Apr 15, 2025, 11:47 AM EDT - 5 months ago

EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease

Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price Tag

Apr 9, 2025, 5:34 AM EDT - 5 months ago

Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price Tag

SAGE

Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease

Apr 2, 2025, 7:30 AM EDT - 5 months ago

Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease

Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.

Mar 27, 2025, 10:22 AM EDT - 6 months ago

Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.

ABBV AMGN BMY GILD IHE JNJ LLY

dogDazeSummer
dogDazeSummer Sep. 14 at 4:18 PM
$IFRX $RHHBY $BIIB https://www.sciencedirect.com/science/article/abs/pii/S2387020625003985 Major need for more AAV solutions. Stadison knows the mechanism works as its FDA approved - low hanging fruit.
1 · Reply
GettnFibbywIT
GettnFibbywIT Sep. 12 at 6:06 AM
$BIIB $XLV $QQQ
0 · Reply
Chingying
Chingying Sep. 11 at 9:54 PM
$BIIB Biogen is finally getting the respect it deserves. If subcutaneous lequembi IQLIK is approved as an alternative for the 18-month treatment regime, it will greatly reduce the world’s burden to manage AZ disease.
0 · Reply
Quantumup
Quantumup Sep. 10 at 6:13 PM
Baird reiterated $SLNO Outperform/$121. Baird said: No change to outlook on FAERS update. The FAERS database was updated and now tragically has a listed death due to pulmonary embolism in a patient who was 17 years old, which management noted in an 8-K was considered by the physician to be not related to Vykat XR. Given comorbidities likely increasing baseline risk (lymphedema, superficial thrombophlebitis, obesity) and the physician's report as unrelated, we think the selloff here is far overdone and presents an even more attractive opportunity for investors to buy the launch on sale. $AARD $RYTM $ACAD $BIIB
0 · Reply
Quantumup
Quantumup Sep. 10 at 5:54 PM
TD Cowen reiterated $SLNO Buy/$120. TD Cowen said in its note: Three new SAEs for Vykat XR were uploaded to the FAERS database, which included a highly unfortunate death related to pulmonary embolism. The reporting physician does not consider this event as treatment-related, and $SLNO's assessment is the same. Pulmonary embolism risk is significantly increased in PWS and obese patients, and per our dinner with management last night, safety remains consistent. $AARD $RYTM $ACAD $BIIB
0 · Reply
iQuicky
iQuicky Sep. 9 at 9:30 PM
$BIIB coming back from death?
0 · Reply
StockAutoPro
StockAutoPro Sep. 9 at 7:50 PM
$BIIB: Buy target $141.05 Sell target $150.2 Strong drug pipeline suggests potential growth for this prominent biotechnology company.
0 · Reply
intrader
intrader Sep. 9 at 2:25 PM
$AVXL $BIIB $LLY $SNY
0 · Reply
Power2k
Power2k Sep. 9 at 2:09 PM
$AVXL No other Alzheimer's efficacy data (from any trials by $BIIB, $LLY, or $SNY ) ever came close to the data released by AVXL today. EMA approval is imminent.
1 · Reply
GettnFibbywIT
GettnFibbywIT Sep. 9 at 1:20 PM
$BIIB $XLV $QQQ Biogen, In.c / Daily: Rising, but still within (so far) the context of a longer term downtrend. A break /close above the upper channel/resistance line on continued underlying strength would initially suggest the trend "may" be changing....
0 · Reply
theDIOyears
theDIOyears Sep. 8 at 3:21 PM
$BIIB good CC today. Started off Rocky with the talk of tariffs and patent exposure etc. But as the talk continued and shifted into the clinical profile and patient population of various diseases, all is good.
0 · Reply
StockAutoPro
StockAutoPro Sep. 8 at 2:14 PM
$BIIB: Buy target $136.45 Sell target $145.37 Consider selling shares in this leading biotech firm due to recent disappointing Alzheimer's drug trials.
0 · Reply
StockAutoPro
StockAutoPro Sep. 7 at 11:45 PM
$BIIB: Buy target $138.67 Sell target $147.7 Potential growth seen in biotech sector due to increased investment in Alzheimer's research.
0 · Reply
forprofit12
forprofit12 Sep. 5 at 4:39 PM
$BIIB what a miserable PoS stock. Nothing moves this POS.
0 · Reply
iQuicky
iQuicky Sep. 5 at 1:12 PM
$BIIB good news coming?
0 · Reply
StockAutoPro
StockAutoPro Sep. 4 at 2:39 PM
$BIIB: Buy target $137.89 Sell target $146.88 Robust drug pipeline could signal potential growth for this leading biotech firm.
0 · Reply
DonCorleone77
DonCorleone77 Sep. 4 at 11:17 AM
$CCCC $BIIB C4 Therapeutics announces Biogen had its IND for BIIB142 accepted by FDA
0 · Reply
JarvisFlow
JarvisFlow Sep. 4 at 10:30 AM
Needham has adjusted their stance on Biogen ( $BIIB ), setting the rating to Hold.
0 · Reply
Chingying
Chingying Sep. 3 at 6:57 PM
$BIIB This will be a big game changer if Rolling submission on fast track for once weekly subcutaneous Leqembi IQLIK autoinjector wins FDA approval to treat AZ disease from the start at home. IQLIK just won approval as maintenance dose on 08/29/2025.
1 · Reply
scientificway
scientificway Sep. 3 at 3:41 PM
$BIIB strong buy. PMN, Have cash and good result. Should be 0.5-14 turn 1000 to 2000
0 · Reply
iQuicky
iQuicky Sep. 3 at 1:55 PM
$BIIB what’s going on?
0 · Reply
GuruLulu
GuruLulu Sep. 3 at 1:51 PM
$BIIB very nice
0 · Reply